SYNIMMUNE Competitors and Similar CompaniesClear all

SYNIMMUNE's competitors and similar companies include Ascendis Pharma, TRON and Allogene Therapeutics.
SYNIMMUNE
SYNIMMUNE
SYNIMMUNE is a biotechnology company dedicated to the development of mono- and bispecific anti-tumor antibodies.
Ascendis Pharma
Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.
TRON
TRON
TRON Mainz is a biopharmaceutical research organization that offers diagnostics and drugs for the treatment of cancer and other severe diseases.
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
Founding Date
Founding Date
2010
Founding Date
2007
Founding Date
2010
Founding Date
2018
Type
Type
Private
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Tübingen, DE HQ
Locations
Hellerup, DK HQ
Heidelberg, DE
Palo Alto, US
Locations
Mainz, DE HQ
Locations
South San Francisco, US HQ
Employees
Employees
5
Employees
1,017
Employees
1903% increase
Employees
2263% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
7.7 b
Valuation ($)
N/A
Valuation ($)
585.5 m

Financial

Net income
Net income
N/A
Net income
(€228m) (FY, 2025)
Net income
N/A
Net income
($190.9m) (FY, 2025)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 85.8m
Total funding raised
N/A
Total funding raised
$ 532m
For sources of this data, please see the company profile

View Company Profiles

Ascendis Pharma
HQ
Hellerup, DK
Employees
1,017

Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.

View company
TRON
HQ
Mainz, DE
Employees
190↑ 3% increase

TRON Mainz is a biopharmaceutical research organization that offers diagnostics and drugs for the treatment of cancer and other severe diseases.

View company
Allogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.

View company